Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Table 6 Clinical responses

Patient no.	Stage	Clinical response*		Number of vac.	CR duration period (year)	PFS (days)	OS (days)	Outcome
Patient no.	Stage	8^thvac.	Final results	Number of vac.	CR duration period (year)	PFS (days)	OS (days)	Outcome
1	IIA	CR	CR	22	4.5	1659	1775	Alive
2	IIB	CR	CR	85	4.6	1681	1709	Alive
3	IVA	PD	PD	8		67	154	Dead
4	III	PD	PD	8		84	123	Dead
5	III	CR	PD	12		127	765	Dead
6	III	CR	CR	69	2.9	1072	1234	Alive
7	IIB	CR	PD	26	2.0	733	1105	Alive
8	IVB	PD	PD	10		176	231	Dead
9	IVB	PD	PD	8		59	300	Dead
10	III	CR	CR	36	1.1	384	660	Alive
11	IVB	PD	PD	15		155	217	Dead

*Clinical responses of patients were analyzed after the 8^th vaccination and the latest diagnosis points. CR: complete response; PD: progressive disease; PFS: Progression-free survival; OS: overall survival.

ISSN: 1479-5876